These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8597746)

  • 1. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
    Olanow CW; Godbold JH; Koller W
    BMJ; 1996 Mar; 312(7032):702-3; author reply 704-5. PubMed ID: 8597746
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline is effective and safe in early stages.
    MacMahon DG; Bland R
    BMJ; 1996 Mar; 312(7032):703; author reply 704-5. PubMed ID: 8597748
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality.
    Mäki-Ikola O; Kilkku O; Heinonen E
    BMJ; 1996 Mar; 312(7032):702; author reply 704-5. PubMed ID: 8597744
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used.
    Gerlach M; Riederer P; Vogt H
    BMJ; 1996 Mar; 312(7032):704; author reply 704-5. PubMed ID: 8597750
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients.
    Anderson KE; Girdwood AC; Wilson JA
    BMJ; 1996 Mar; 312(7032):702; author reply 704-5. PubMed ID: 8597745
    [No Abstract]   [Full Text] [Related]  

  • 6. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations.
    Yu PH; Lai CT; Boulton AA
    BMJ; 1996 Mar; 312(7032):703-4; author reply 704-5. PubMed ID: 8597749
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation.
    Jellinger KA
    BMJ; 1996 Mar; 312(7032):704-5. PubMed ID: 8597751
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death.
    Silva MT; Watts PM; Jenner P
    BMJ; 1996 Mar; 312(7032):703; author reply 704-5. PubMed ID: 8597747
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drug therapy of Parkinson disease].
    Dietrichs E
    Tidsskr Nor Laegeforen; 1992 Oct; 112(24):3106-9. PubMed ID: 1471089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK
    Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
    Dubois B; Montastruc JL
    Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
    [No Abstract]   [Full Text] [Related]  

  • 15. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selegiline and mortality in Parkinson's disease.
    Olanow CW; Fahn S; Langston JW; Godbold J
    Ann Neurol; 1996 Dec; 40(6):841-5. PubMed ID: 9007088
    [No Abstract]   [Full Text] [Related]  

  • 17. Strategies in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1993; 146():50-3. PubMed ID: 8101417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Parkinson's disease.
    Bergus G
    J Fam Pract; 1996 May; 42(5):457-8. PubMed ID: 8642360
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.